QuidelOrtho (NASDAQ:QDEL) Shares Up 6.9% - Here's What Happened

Key Points

• QuidelOrtho shares rose 6.9% to approximately $14.75, although trading volume was 81% below the stock’s average daily volume.
• Analyst sentiment remains cautious: the stock has a consensus rating of “Reduce” with an average price target of $13.62, below its latest trading price.
• QuidelOrtho exceeded quarterly expectations, reporting $0.13 in EPS versus a projected loss of $0.05 and revenue of $630.9 million versus estimates of $618.72 million; full-year 2026 EPS guidance is $0.65–$0.90.

QuidelOrtho Corporation (NASDAQ:QDEL - Get Free Report)'s share price traded up 6.9% on Thursday . The company traded as high as $14.68 and last traded at $14.7510. 332,858 shares traded hands during mid-day trading, a decline of 81% from the average daily volume of 1,756,670 shares. The stock had previously closed at $13.80.

Wall Street Analyst Weigh In

QDEL has been the topic of a number of recent analyst reports. Jefferies Financial Group reaffirmed a "hold" rating on shares of QuidelOrtho in a report on Monday, June 29th. JPMorgan Chase & Co. raised their target price on QuidelOrtho from $11.00 to $12.00 and gave the company an "underweight" rating in a report on Wednesday, July 1st. Weiss Ratings restated a "sell (e+)" rating on shares of QuidelOrtho in a research report on Friday, July 17th. Wall Street Zen raised shares of QuidelOrtho from a "sell" rating to a "hold" rating in a research note on Sunday, June 28th. Finally, Citigroup upped their price target on shares of QuidelOrtho from $13.00 to $18.00 and gave the stock a "neutral" rating in a research note on Wednesday, July 8th. Three analysts have rated the stock with a Hold rating and three have issued a Sell rating to the company. According to MarketBeat.com, the stock presently has a consensus rating of "Reduce" and a consensus target price of $13.62.

QuidelOrtho Price Performance

The company has a 50 day moving average price of $15.80 and a 200 day moving average price of $16.61. The firm has a market cap of $1.02 billion, a PE ratio of -0.96 and a beta of 0.68. The company has a current ratio of 1.39, a quick ratio of 0.76 and a debt-to-equity ratio of 1.43.

QuidelOrtho (NASDAQ:QDEL - Get Free Report) last released its quarterly earnings data on Thursday, August 6th. The company reported $0.13 earnings per share for the quarter, beating the consensus estimate of ($0.05) by $0.18. The firm had revenue of $630.90 million during the quarter, compared to the consensus estimate of $618.72 million. QuidelOrtho had a positive return on equity of 4.88% and a negative net margin of 39.20%.QuidelOrtho's quarterly revenue was up 2.8% on a year-over-year basis. During the same period last year, the business posted $0.12 EPS. QuidelOrtho has set its FY 2026 guidance at 0.650-0.900 EPS. On average, sell-side analysts expect that QuidelOrtho Corporation will post 0.75 EPS for the current year.

Institutional Investors Weigh In On QuidelOrtho

Several institutional investors and hedge funds have recently made changes to their positions in the business. Global Retirement Partners LLC increased its holdings in QuidelOrtho by 3,691.7% during the 4th quarter. Global Retirement Partners LLC now owns 910 shares of the company's stock valued at $26,000 after acquiring an additional 886 shares in the last quarter. Camelot Portfolios LLC purchased a new stake in shares of QuidelOrtho in the fourth quarter valued at about $29,000. Hantz Financial Services Inc. grew its position in shares of QuidelOrtho by 50.3% in the fourth quarter. Hantz Financial Services Inc. now owns 1,082 shares of the company's stock valued at $31,000 after purchasing an additional 362 shares during the last quarter. Larson Financial Group LLC grew its position in shares of QuidelOrtho by 322.2% in the third quarter. Larson Financial Group LLC now owns 1,330 shares of the company's stock valued at $39,000 after purchasing an additional 1,015 shares during the last quarter. Finally, GAMMA Investing LLC increased its stake in shares of QuidelOrtho by 67.7% during the 2nd quarter. GAMMA Investing LLC now owns 2,185 shares of the company's stock worth $38,000 after purchasing an additional 882 shares in the last quarter. 99.00% of the stock is currently owned by hedge funds and other institutional investors.

About QuidelOrtho

QuidelOrtho is a global diagnostics company formed through the merger of Quidel Corporation and Ortho Clinical Diagnostics. The combined entity develops, manufactures and markets a broad portfolio of rapid and high-throughput diagnostic solutions across immunoassay, molecular diagnostics and transfusion medicine. Its offerings span point-of-care platforms for acute care testing as well as large-scale automated systems designed for clinical laboratories and blood banks.

The company's product range includes rapid antigen and antibody tests for infectious diseases, molecular assays utilizing nucleic acid amplification technology, and integrated immunodiagnostic analyzers.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source